Stock Events

Stock Events

Codexis 

€1.95
59
+€0.05+2.86% Today

Statistics

Day High
1.96
Day Low
1.87
52W High
2.83
52W Low
0.82
Volume
0
Avg. Volume
280
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q4 2025
Next
-0.13
-0.05
0.02
0.1
Expected EPS
-0.12505484
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4QK.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Zymeworks BC
ZYME
Mkt Cap1.96B
Zymeworks Inc. is involved in the development of biotherapeutics, competing with Codexis in the biocatalyst market for pharmaceuticals.
Evotec
EVO
Mkt Cap941.38M
Evogene Ltd. focuses on the development of products for various life science markets, including the use of computational predictive biology, overlapping with Codexis' enzyme optimization technologies.
BNY Mellon Strategic Municipal Bond Fund
DSM
Mkt Cap0
Koninklijke DSM N.V. is a global science-based company active in health, nutrition, and materials, including biotechnology solutions that compete with Codexis' offerings.
Novonesis AS
NVZMY
Mkt Cap28.23B
Novozymes A/S is a world leader in bioinnovation and industrial enzymes, directly competing with Codexis in the development and production of novel enzymes.
DuPont de Nemours
DD
Mkt Cap19.8B
DuPont de Nemours, Inc. offers technology-based materials, ingredients, and solutions, including biotechnology products that compete with Codexis in the industrial biotech space.
Symrise
SYIEY
Mkt Cap12.02B
Symrise AG is engaged in producing flavors and fragrances, enzymes, and cosmetic ingredients, competing with Codexis in the specialty enzymes market.

About

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Show more...
CEO
Dr. Alison Moore Ph.D.
Employees
146
Country
United States
ISIN
US1920051067

Listings

STU
DE
4QK.STU
F
DE
4QK.F
MU
DE
4QK.MU
XNAS
US
CDXS

0 Comments

Share your thoughts

FAQ

What is Codexis stock price today?▼
The current price of 4QK.STU is €1.95 EUR — it has increased by +2.86% in the past 24 hours. Watch Codexis stock price performance more closely on the chart.
What is Codexis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Codexis stocks are traded under the ticker 4QK.STU.
Is Codexis stock price growing?▼
4QK.STU stock has risen by +21.49% compared to the previous week, the month change is a +35.92% rise, over the last year Codexis has showed a -7.81% decrease.
When is the next Codexis earnings date?▼
Codexis is going to release the next earnings report on April 30, 2026.
What were Codexis earnings last quarter?▼
4QK.STU earnings for the last quarter are 0.1 EUR per share, whereas the estimation was -0.03 EUR resulting in a +466.67% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Codexis have?▼
As of April 13, 2026, the company has 146 employees.
In which sector is Codexis located?▼
Codexis operates in the Health & Wellness sector.
When did Codexis complete a stock split?▼
Codexis has not had any recent stock splits.
Where is Codexis headquartered?▼
Codexis is headquartered in Redwood City, United States.